EMVISION MEDICAL DEVICES LIMITED (EMV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EMV

EMV - EMVISION MEDICAL DEVICES LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.26
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.98

08 Sep
2025

-0.010

OPEN

$1.98

-0.50%

HIGH

$1.98

109,042

LOW

$1.91

TARGET
$2.95 49.0% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
EMV: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 11.5 - 9.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-11.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx10.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-7.8 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-70.55 %
Return on Invested Capital xxxxxxxxxxxxxxx-59.52 %
Return on Assets xxxxxxxxxxxxxxx-49.59 %
Return on Equity xxxxxxxxxxxxxxx-70.55 %
Return on Total Capital xxxxxxxxxxxxxxx-81.18 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx4 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx11 M
Price To Book Value xxxxxxxxxxxxxxx16.03

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx4 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

01/09/2025

1

Speculative Buy

$2.95

48.99%

Nothing to see in EMVision Medical Devices' FY25 result, with cash balance of $10.5m and operating cash flow of -$7.8m.

The focus is on progress in the two key products, and Bell Potter notes a sixth pivotal site has been added for the emu brain scanning product. A network of six leading international stroke centres, including the latest UCLA Health, has now been formed.

Initial aeromedical testing was completed with Royal Flying Doctor Service and Australian Stroke Alliance for the First Responder device, demonstrating robustness and suitability under demanding conditions.

The broker notes more studies are due in 1H26, which would finally support the FDA clearance pathway.

Speculative Buy. Target unchanged at $2.95.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -9.20 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -10.70 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

EMV STOCK CHART

FNArena News on EMV

1
FNArena Corporate Results Monitor – 01-09-2025

Sep 01 2025 - Australia
2
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
3
Australian Broker Call *Extra* Edition – Feb 06, 2023

Feb 06 2023 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Nov 16, 2022

Nov 16 2022 - Daily Market Reports
5
Who Will Be The Next Pro Medicus?

May 13 2021 - Weekly Reports

Latest Medical Equipment & Devices News

1
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
2
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
3
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
4
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
5
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
6
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
7
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
8
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
9
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
10
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia